2020 American Transplant Congress
Treatment of De Novo Renal Transplant Recipients with Calcineurin Inhibitor (CNI)-Free, Belatacept+Everolimus-Based Immunosuppression
*Purpose: Compared with CNI-based immunosuppression, kidney transplant recipients receiving belatacept-based treatment present with a favorable metabolic profile, reduced chronic allograft nephropathy, and improved renal function,…2020 American Transplant Congress
Medication Knowledge Retention and Adherence Following Transplant: Is There Room for Improvement?
*Purpose: Transplant recipients’ complex medication regimens following transplant can lead to non-adherence, which has been linked to increased rates of acute rejection and graft loss.…2020 American Transplant Congress
Clinical Outcomes in Kidney Transplant Recipients Following Implementation of a Strategic Maintenance Reduction Protocol
Pharmacy, Medical University of South Carolina, Charleston, SC
*Purpose: Post-transplant complications are commonly due to over-immunosuppression, particularly as it relates to infections. The purpose of this study was to assess clinical outcomes in…2020 American Transplant Congress
Association of Discharge Immunosuppressive Regimen with Treated Acute Rejection and Bronchiolitis Obliterans Syndrome in Adult Lung Transplantation: An Analysis of Organ Procurement and Transplantation Network Data
*Purpose: The optimal immunosuppressive (IS) regimen after lung (LU) transplant is unknown. We conducted the current analysis to compare the effect of four different discharge…2020 American Transplant Congress
Quantitative Analysis of Humoral Immunity by Flow-Cytometric Crossmatch Using Molecules of Equivalent Soluble Fluorochromosome (FCXM-MESF)
*Purpose: In this study, we examined the quantitative significance of humoral immunity by flow-cytometric crossmatch using molecules of equivalent soluble fluorochromosome (FCXM-MESF) in recipients of…2020 American Transplant Congress
Precision Dosing for Tacrolimus Using Genotypes and Clinical Factors
*Purpose: Variants in CYP3A4/5 genes, clinical factors and drug-drug interactions are associated with tacrolimus (TAC) clearance and dose. This results in high intra- and inter-…2020 American Transplant Congress
Lymphycyte Subset Test as a Determinant of Cytomegalovirus Prophylaxis in Renal Transplant Recipients
Surgery, The Catholic University of Korea, Seoul, Korea, Republic of
*Purpose: Cytomegalovirus (CMV) infection is an important complication after kidney transplantation (KT). Anti-thymocyte globulin (ATG) increases a risk of CMV infection and the American society…2020 American Transplant Congress
Incident Malignancies among Post Kidney-Transplant Patients by Type of Induction Immunosuppression and by Age
Johns Hopkins University, Baltimore, MD
*Purpose: Adult kidney-transplant (KT) recipients have a differential risk of malignancies based on their induction immunosuppression (IS) therapy. However, older recipients are more likely to…2020 American Transplant Congress
Stability of T Reg with Combination of mTOR Inhibitors with Belatacept in Reducing Risk of Acute Rejection in Kidney Transplant
University of California San Francisco (UCSF), San Francisco, CA
*Purpose: Belatacept is a costimulatory blocker that is used as de novo maintenance immunosuppression in kidney transplantation to avoid toxic effects of calcineurin inhibitors and…2020 American Transplant Congress
ATHENA – Patient and Allograft Outcome Differences after Kidney Transplantation – Germany vs. France
*Purpose: In the ATHENA trial [NCT01843348], efficacy and safety of everolimus in combination with tacrolimus [EVR+TAC] or cyclosporine A [EVR+CyA] vs. TAC and mycophenolic acid…
- « Previous Page
- 1
- …
- 29
- 30
- 31
- 32
- 33
- …
- 138
- Next Page »